Ninety-day oral toxicity studies on two genetically modified maize MON810 varieties in Wistar Han RCC rats (EU 7th Framework Programme project GRACE) by Zeljenková, Dagmar et al.
1 3
Arch Toxicol (2014) 88:2289–2314
DOI 10.1007/s00204-014-1374-8
BIOLOGICS
Ninety‑day oral toxicity studies on two genetically modified maize 
MON810 varieties in Wistar Han RCC rats (EU 7th Framework 
Programme project GRACE)
Dagmar Zeljenková · Katarína Ambrušová · Mária Bartušová · Anton Kebis · Jevgenij Kovrižnych · 
Zora Krivošíková · Miroslava Kuricová · Aurélia Líšková · Eva Rollerová · Viera Spustová · Elena Szabová · 
Jana Tulinská · Sonˇa Wimmerová · Mikuláš Levkut · Viera Révajová · Zuzana Ševcˇíková · Kerstin Schmidt · 
Jörg Schmidtke · Jose Luis La Paz · Maria Corujo · Maria Pla · Gijs A. Kleter · Esther J. Kok · Jutta Sharbati · 
Carlos Hanisch · Ralf Einspanier · Karine Adel‑Patient · Jean‑Michel Wal · Armin Spök · Annette Pöting · 
Christian Kohl · Ralf Wilhelm · Joachim Schiemann · Pablo Steinberg 
Received: 28 July 2014 / Accepted: 15 September 2014 / Published online: 2 October 2014 
© The Author(s) 2014. This article is published with open access at Springerlink.com
obtained show that the MON810 maize at a level of up to 
33 % in the diet did not induce adverse effects in male and 
female Wistar Han RCC rats after subchronic exposure, 
independently of the two different genetic backgrounds of 
the event.
Keywords Food/Feed Guidance Document of the EFSA 
Scientific Committee (2011) · Genetically modified maize 
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Introduction
The new Implementing Regulation (EU) No. 503/2013 
(Implementing Regulation (EU) 2013) describing in detail 
the risk assessment requirements for pre-market authori-
sation of genetically modified (GM) food and feed in the 
Abstract The GMO Risk Assessment and Communica-
tion of Evidence (GRACE; www.grace-fp7.eu) project is 
funded by the European Commission within the 7th Frame-
work Programme. A key objective of GRACE is to con-
duct 90-day animal feeding trials, animal studies with an 
extended time frame as well as analytical, in vitro and in 
silico studies on genetically modified (GM) maize in order 
to comparatively evaluate their use in GM plant risk assess-
ment. In the present study, the results of two 90-day feed-
ing trials with two different GM maize MON810 varieties, 
their near-isogenic non-GM varieties and four additional 
conventional maize varieties are presented. The feeding 
trials were performed by taking into account the guidance 
for such studies published by the EFSA Scientific Commit-
tee in 2011 and the OECD Test Guideline 408. The results 
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European Union became effective in December 2013. 
Thereby, a previously used EFSA guidance document was 
replaced by statutory legislation. Regarding the toxicologi-
cal assessment of GM plants, a major novelty in the above-
mentioned Implementing Regulation is the incorporation of 
a mandatory 90-day rodent feeding study for single trans-
formation events (Implementing Regulation (EU) 2013; 
Waigmann et al. 2013).
Following a request from the European Commission, 
the Scientific Committee of the European Food Safety 
Authority (EFSA) developed principles and guidance for 
the establishment of protocols for 90-day whole food/feed 
studies in rodents (EFSA Scientific Committee 2011). 
This guidance represents a further development of the 
OECD Guideline for the Testing of Chemicals—Repeated-
dose 90-day oral toxicity study in rodents (OECD TG 
408; OECD 1998) describing the procedure to test the 
subchronic toxicity of chemicals in rodents, and provides 
advice on how to perform and report experiments carried 
out with whole food/feed. The main recommendations of 
the EFSA guidance are as follows: (1) the study should 
be performed and documented by following good labora-
tory practice (GLP); (2) an appropriate characterisation 
of the whole food/feed to be tested is required and should 
include, among others, a description of the source, its 
composition, the manufacturing process, information on 
stability and the presence of chemical and/or microbiolog-
ical contaminants; (3) one control group (when testing GM 
food/feed the isogenic or near-isogenic control) and two 
dose levels (low and high) of the whole food/feed should 
be tested, whereby the low dose level should always be 
above the anticipated human/target animal intake level and 
the high dose level should not lead to a nutritional imbal-
ance or to metabolic disturbances in the test animals; (4) 
animals of the same sex should be housed in pairs and the 
experimental unit is therefore a cage containing two ani-
mals; (5) the 90-day study should be conducted with the 
full range of observations as described in the OECD TG 
408; (6) the endpoints should be examined for all ani-
mals, except for histopathology, which initially should 
be performed on the control and high dose test group (in 
the case of GM food/feed); if histopathological differ-
ences between the control and the high dose test group are 
observed, those from other groups should also be exam-
ined; (7) a randomised block design is recommended for 
90-day toxicity studies when testing whole food/feed; and 
(8) a power analysis to estimate an appropriate sample 
size capable of detecting a pre-specified biologically rel-
evant effect size with a specified power and significance 
level should be performed. EFSA emphasised at that time 
that the guidance was not intended to provide a prescrip-
tive experimental test protocol to carry out a 90-day feed-
ing study with whole food/feed, but should be viewed as a 
help to design, conduct, analyse, report and interpret such 
studies.
A key objective of the GRACE (GMO Risk Assess-
ment and Communication of Evidence; www.grace-fp7.
eu) project, which is funded by the European Commission 
within the 7th Framework Programme, is to comparatively 
evaluate the use of 90-day animal feeding trials, animal 
studies with an extended time frame as well as analytical, 
in vitro and in silico studies on GM maize in GMO risk 
assessment. In the present study, the results of two 90-day 
feeding trials with two different GM maize MON810 
varieties performed by taking into account the guidance 
for such studies published by the EFSA Scientific Com-
mittee in 2011 and the OECD TG 408 are presented. The 
transgenic trait MON810 consists of a Bacillus thuring-
iensis (Bt)-derived gene, namely a truncated cry1Ab gene 
encoding an insecticidal protein (δ-endotoxin; Schnepf 
et al. 1998), for the control of some lepidopteran insect 
pests such as the European corn borer (Ostrinia nubilalis; 
Hill et al. 1995). The two selected varieties were the two 
most widely used by farmers in Catalonia, Spain, and were 
chosen to explore whether the genetic background had an 
influence on the outcome of the feeding trials. In each feed-
ing trial, not only the corresponding near-isogenic non-GM 
maize variety but also two additional conventional maize 
varieties were tested, since the Slovak Medical University 
(Bratislava, Slovakia), the institution conducting the feed-
ing trials, had not performed such studies with maize in the 
past, and therefore, appropriate historical data with which 
one could compare the results obtained in the present study 
were lacking. Moreover, by including two additional con-
ventional maize varieties in each feeding trial, information 
regarding the inherent variability of the results obtained 
with different conventional maize varieties was gathered. 
The feeding trials were conducted as two different studies 
to test whether independent trials with the same event pro-
vide the same conclusions regarding event-specific effects.
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The interpretation of the results and conclusions in this 
paper is limited to the toxicological relevance of the differ-
ences detected between the GM and non-GM maize varie-
ties. General conclusions on the value of the 90-day studies 
for GMO risk assessment versus alternative approaches and 
studies with extended time frames will be drawn once all 
relevant GRACE project results are available.
Materials and methods
Plant material
Maize was produced in Pla de Foixa (Girona, Catalonia, 
Spain, 42°05′N, 3°E) during the growing season of 2012. 
This area is close to the sea and has a Mediterranean cli-
mate. The soil type is Xerofluven oxiaquic, coarse-loamy, 
mixed, calcareous and thermic. A total of eight commercial 
varieties were produced, all commercially cultivated in that 
region: two GM maize MON810 and their near-isogenic 
non-GM varieties as well as four additional conventional 
varieties (Table 1). The seeds were purchased at the local 
market. About 1 ha of each MON810 and near-isogenic 
variety and 500 m2 each of the four additional varieties 
were sown. There was no maize cultured in neighbouring 
fields that had been sown at the same period of time, so that 
the probability of cross-pollination was minimised. Maize 
was cultivated following standard agricultural practices in 
the area; 600 kg N, P and K per ha (15-15-15 NPK) were 
applied before sowing. Weeds were controlled by pre-emer-
gence application of 4 L HARNESS® GTZ per ha (41 % 
acetochlor + 19.5 % terbuthylazine) and by post-emer-
gence application of 1 L Callisto® per ha (480 g/L meso-
trione). No insecticide was applied. In-furrow irrigations 
were supplied when needed during the cropping season. 
Maize was planted at a density of 80,000 plants ha−1 with 
75-cm row spacing.
Agronomic, morphologic, phenological and health 
parameters were monitored and were as usual in the 
region. Specifically, Sesamia nonagrioides and Ostrinia 
nubilalis infestation was below 0.4 %, and there was no 
relevant fungal or viral infection. A very good yield (i.e. 
13,000–14,000 kg/ha) was achieved. Meteorological data 
were recorded (Electronic Supplementary Material, Fig-
ure 1). The central part of each plot was independently har-
vested, and kernels were removed from the cobs on-site by 
machine. They had grain moisture levels in the usual range 
(i.e. 18–24 %) and were dried in a forced-air laboratory 
oven for 1–2 days down to a moisture level of about 10 %.
Diet preparation and analyses
Batches of 35–90 kg per maize variety were transported to 
Mucedola srl (Milan, Italy). The kernels were then milled 
(mesh size: 1 mm), coded and used to prepare the feed. 
The formulation of the diets was isoproteic, isocaloric and 
adjusted to the dietary requirements of the rat strain Wistar 
Han RCC used in the feeding trials. Besides the milled 
maize, the formulation mainly consisted of other plant-
derived ingredients, including wheat, wheat middlings, 
soybean meal and soy oil, while it did not contain animal-
derived ingredients. Ten different diets in pellet form were 
prepared (Table 1), whereby the resulting pellets were dried 
at a temperature <50 °C, coded in a blinded fashion and 
sent to the Slovak Medical University (Bratislava, Slova-
kia) for the feeding trials as vacuum-packed, γ-irradiated 
batches (irradiation dose = 25 kGy).
Milled maize and diet samples (1.5 kg each) were sent 
to RIKILT (Institute for Food Safety, Wageningen Univer-
sity, Wageningen, The Netherlands), where the feed pellets 
were milled and re-mixed. Thereafter, subsamples were 
dispatched to Covance (Madison, WI, USA), Mucedola and 
INRA (Laboratoire d’Immuno-Allergie Alimentaire, CEA 
Saclay, Gif-Sur-Ivette, France). Before dispatch to RIKILT, 
smaller maize and diet subsamples were retained at the 
animal feed producing facility (Mucedola srl) for analy-
sis. A list of the parameters measured, the analytical meth-
ods used and the institutions that performed the individual 
Table 1  Maize variety content of the different diets used in the rat 
feeding trials A and B
a
 Near-isogenic maize variety of DKC6667 YG, from Monsanto
b
 Transgenic maize variety (MON 810), from Monsanto
c
 Conventional maize variety, from Pioneer Hi-Bred
d
 Conventional maize variety, from Koipesol Semillas
e
 Near-isogenic maize variety of PR33D48, from Pioneer Hi-Bred
f
 Transgenic maize variety (MON 810), from Pioneer Hi-Bred
g
 Conventional maize variety, from Monsanto
Diet Maize variety content (%)
Feeding trial A
 33 % near-isogenic non-GM maize 33 % DKC6666a
 11 % MON 810 11 % DKC6667-YGb  
+ 22 % DKC6666
 33 % MON 810 33 % DKC6667-YG
 33 % conventional 1 33 % PR33W82c
 33 % conventional 2 33 % SY NEPALd
Feeding trial B
 33 % near-isogenic non-GM maize 33 % PR32T16e
 11 % MON 810 11 % PR33D48f  
+ 22 % PR32T16
 33 % MON 810 33 % PR33D48
 33 % conventional 1 33 % PR32T83c
 33 % conventional 2 33 % DKC6815g
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analyses is shown in Table 1 of the Electronic Supplemen-
tary Material. The feed analyses were performed under 
GLP conditions.
Study design
The sample size calculation is based on the standardised 
effect size [SES: the difference in means between control 
and treated groups divided by the standard deviation (SD)]. 
It was assumed that an SES of 1.0 SD or less is unlikely to 
be of toxicological importance. Assuming a power of 0.8, a 
significance level of 0.05 and a two-sided test, this would 
be achieved by 17 animals per group. The number was 
rounded down to an even number (i.e. 16) as the rats were 
to be housed in pairs.
The total number of animals per feeding trial was 160, 
with 16 animals (eight cages) per gender and dietary treat-
ment. Three dietary treatments represent the groups “con-
trol”, “11 % GMO” and “33 % GMO”. Two additional 
groups consisting of two conventional maize varieties with 
the same sample size per gender and group were included. 
Consequently, the factor “group” has five levels, namely 
“control”, “11 % GMO”, “33 % GMO”, “conventional 1” 
and “conventional 2”.
Experimental unit
As recommended by the EFSA guidance on conduct-
ing repeated-dose 90-day oral toxicity study in rodents on 
whole food/feed (EFSA Scientific Committee 2011), two 
animals of the same gender were housed per cage and the 
cage was taken as the experimental unit.
Rat feeding trials
The rat feeding trials A and B were conducted by taking 
into account the EFSA Guidance on conducting repeated-
dose 90-day oral toxicity study in rodents on whole food/
feed (EFSA Scientific Committee 2011) and the OECD TG 
408. The trials were performed in compliance with GLP in 
the experimental animal house at the Department of Toxi-
cology of the Slovak Medical University in Bratislava (Slo-
vakia). Male and female Wistar Han RCC rats, 5 weeks 
old and with a uniform weight (±20 % of the mean), were 
purchased from Harlan (San Pietro al Natisone, Italy), and 
the two studies were started 1 week after delivery of the 
animals at the animal testing facility (i.e. in April 2013, 
the study A 2 weeks ahead of study B). Sixteen animals 
per group were used, two animals were placed in one cage 
(=experimental unit), and each animal was allocated to 
the individual cages by dose group and sex in such a way 
that the average weight between the treatment groups was 
similar. Each feeding trial was started in a stepwise manner 
during four successive days as follows: (1) feeding start for 
males in cages 1–4 of each treatment group on day 1; (2) 
feeding start for males in cages 5–8 of each treatment group 
on day 2; (3) feeding start for females in cages 1–4 of each 
treatment group on day 3; and (4) feeding start for females 
in cages 5–8 of each treatment group day 4. A detailed 
examination of all animals to verify their health condition 
(see the section Periodical health status observations) was 
carried out just before the start of the feeding trials. Feed 
and water were supplied ad libitum. Feed consumption was 
determined once weekly and reported as the total amount 
of feed consumed by two animals in one cage per week.
Periodical health status observations
Rats were inspected twice daily for changes in skin, fur, 
eyes, mucous membranes, occurrence of secretions and 
excretions as well as activity level and change in behav-
iour. A detailed physical examination of each animal out of 
the cage was performed once weekly to identify changes 
in skin, fur, eyes, mucous membranes, occurrence of secre-
tions and excretions, autonomic activity such as lacrima-
tion, piloerection, pupil size, unusual respiratory patterns as 
well as activity level and change in behaviour. At the end 
of the feeding trials, a functional assessment of changes in 
gait, posture and response to handling as well as the pres-
ence of clonic or tonic movements or bizarre behaviour 
(self-mutilation, walking backwards) was carried out. Sen-
sory reactivity to auditory, visual and proprioceptive stim-
uli was recorded. An ophthalmologic examination of both 
eyes of all animals in the conscious state was performed 
in week 1 and 12. The eyes and the peribulbar structures 
were examined macroscopically after pupillary dilatation 
induced by instillation of a 0.5 % tropicamide solution. 
Each animal was weighed 48 h after its arrival at the exper-
imental animal house of the Slovak Medical University, on 
the first day of the feeding trial, once weekly during the 
feeding trial and at the end of the feeding trial.
Haematology and clinical biochemistry analyses
For the haematology analyses, blood was taken from the 
tail vein of the rats 1 week before killing, whereby the 
animals were not fasted, and EDTA was used as antico-
agulant. The order in which blood samples were taken for 
the haematology analyses is shown in Tables 2 and 3 of the 
Electronic Supplementary Material. No later than 4 h after 
collection of the blood samples, the following haematol-
ogy parameters were measured by making use of a Sys-
mex K-4500 automated haematology analyser (Sysmex, 
Kobe, Japan): white blood cell count (WBC), red blood cell 
count (RBC), haemoglobin concentration (HGB), haema-
tocrit (HCT), mean cell volume (MCV), mean corpuscular 
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haemoglobin (MCH), mean corpuscular haemoglobin con-
centration (MCHC), platelet count (PLT) and lymphocyte 
count (LYM). For the differential leucocyte count, blood 
smears were stained with the May–Grunwald and Giemsa–
Romanowski dyes and thereafter examined by light 
microscopy; the percentage of lymphocytes, neutrophils, 
eosinophils, basophils and monocytes were determined by 
examining 100 cells.
For the clinical biochemistry analyses at the end of the 
study, rats were anaesthetised after an 18-h fasting period 
with 10 mg/kg bw xylazine and 75 mg/kg bw ketamine and 
blood samples were generally taken from the abdominal 
aorta of the rats. Because of complications in the arterial 
blood collection, in the case of two male rats fed the con-
ventional diet 2 and one female rat fed the 33 % GMO diet 
in study A and one female rat fed the control diet in study 
B, blood samples were taken from the inferior vena cava. 
The order in which blood samples were taken for the clini-
cal biochemistry analyses is shown in Tables 2 and 3 of the 
Electronic Supplementary Material. The parameters alka-
line phosphatase (ALP), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), albumin (ALB), total 
protein (TP), glucose (GLU), creatinine (CREA), urea (U), 
cholesterol (CHOL), triglycerides (TRG), calcium (Ca), 
chloride (Cl), potassium (K), sodium (Na) and phospho-
rus (P) were measured maximally 4 h after collection of 
the blood samples in serum with an Ortho Clinical Vitros® 
250 Chemistry System (Ortho-Clinical Diagnostics, Rari-
tan, NJ, USA), whereas coagulation parameters were not 
determined.
Gross necropsy and histopathology
After taking blood samples, the successive necropsy of the 
thoracic cavity, the abdominal cavity, the genital organs 
and, following decapitation, the head was performed. 
The order in which necropsy was performed is shown in 
Tables 2 and 3 of the Electronic Supplementary Mate-
rial. Moreover, the wet weight of the kidneys, spleen, 
liver, adrenal glands, pancreas, lung, heart, thymus, testes, 
epididymides, uterus, ovaries and brain of all animals was 
recorded. Organ samples were stored in neutrally buffered 
10 % formalin and sent to TOPALAB (Košice, Slovakia) 
for their histopathological examination.
A complete microscopic examination of the brain 
(including cerebrum, cerebellum and medulla/pons), spi-
nal cord (at the cervical, mid-thoracic and lumbar level), 
pituitary, thyroid, parathyroid, thymus, oesophagus, sali-
vary glands, stomach, small and large intestines, liver, pan-
creas, kidneys, adrenals, spleen, heart, trachea and lungs 
(preserved by inflation with fixative and then immersion), 
aorta, gonads, uterus, female mammary gland, prostate, uri-
nary bladder, lymph nodes, peripheral nerve, bone marrow 
and skin from all animals in the control and high dose 
groups was performed. In order to do so, the formalin-fixed 
tissue samples were washed, dehydrated and embedded in 
paraffin. Thereafter, 4-µm-thick sections were stained with 
haematoxylin and eosin for the light microscopic examina-
tion of the tissue structure.
Statistics
Mean values per cage were calculated for all endpoints 
except for body weight. Data were screened for outliers and 
extreme values. For each gender group factor level combi-
nation and all variables, box and whisker plots were created 
to identify extreme values (variable values within the 1.5* 
and 3* interquartile range and variable values outside the 
3* interquartile range). Growth curves of all animals were 
plotted (scatter plots, weight against study day) and visu-
ally inspected for irregular patterns [Appendix 2 in Schmidt 
and Schmidtke (2014)]. Some extreme values were identi-
fied, mainly in the haematology and clinical biochemistry 
data sets. Two biochemistry results were excluded due to 
the fact that the measured values were outside the dynamic 
range of the analyser.
To describe the data summary statistics including means, 
standard deviations, 95 % confidence intervals, medians, 
number of valid values, minima and maxima were calcu-
lated and tabulated. Additionally to the box and whisker 
plots, plots of means and 95 % confidence intervals were 
drawn. Descriptive analysis was performed separately 
for each gender and group [Appendix 3 in Schmidt and 
Schmidtke (2014)]. To check whether the data followed a 
normal distribution, the Kolmogorov–Smirnov (with Lil-
liefors correction) and Shapiro–Wilk tests were performed. 
When significances were identified, the corresponding nor-
mal Q–Q plots were displayed [Appendix 4 in Schmidt and 
Schmidtke (2014)].
The two genders were analysed separately, while the 
weight and feed consumption data were analysed by apply-
ing mixed models and using the restricted maximum likeli-
hood (REML) algorithm with Toeplitz covariance structure. 
The group (five levels) was considered a fixed factor. The 
factor week (time in weeks from the start of the experi-
ment) or day (time in days from the start of the experi-
ment) was considered a continuous fixed factor [Appendix 
5 in Schmidt and Schmidtke (2014)]. For all other end-
points, standardised effect sizes [SES: difference in means 
between two groups divided by the pooled standard devia-
tion (SD)] as well as their 95 % confidence intervals were 
calculated according to Nakagawa and Cuthill (2007). Four 
group pairs were compared with each other: control—GMO 
11 %, control—GMO 33 %, control—conventional 1 and 
control—conventional 2. The SES estimates are shown as 
graphs, displaying both the statistical significance and the 
2294 Arch Toxicol (2014) 88:2289–2314
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supposed biological and possible toxicological relevance 
limits for each of the endpoint comparison results. All end-
points are shown in the same graph (separately for male and 
female rats), thereby forming an overall pattern and allow-
ing the assessment of group comparisons at a glance. Fig-
ure 1 shows exemplarily how to interpret the results in the 
individual SES graphs. A bootstrap test was applied to com-
pare the variability within the corresponding paired sets of 
SES [Appendix 6 in Schmidt and Schmidtke (2014)].
The “classical” statistical analysis procedure compares 
endpoints between groups by applying statistical tests. As a 
parametric method, it uses analysis of variance (ANOVA) fol-
lowed by post hoc tests (in most publications either the t test 
or the Dunnett test) or by contrast testing. As a nonparametric 
method, it uses the Kruskal–Wallis and the Wilcoxon tests. It 
is recommended to first check the data for the parametric test-
ing assumptions (normal distribution, variance homogeneity) 
and to subsequently apply parametric methods to variables 
meeting these assumptions, and to apply nonparametric meth-
ods to all other variables. Nevertheless, since ANOVA toler-
ates deviations from the assumptions and parametric tests are 
usually more powerful and versatile, it is sometimes applied 
to all variables. A more conservative approach is to apply 
only nonparametric tests to all variables. To illustrate and 
compare the consequences of applying parametric and non-
parametric methods, we performed ANOVA followed by both 
the t test and the Dunnett test as well as the Kruskal–Wallis 
test followed by the Wilcoxon test to the haematology and 
the clinical biochemistry parameters as well as to the relative 
organ weights. In the Tables 4, 5, 6, 8, 9 and 10 listing the hae-
matology, clinical biochemistry and relative organ weight data 
of the two feeding trials, the significances obtained with the 
“classical” statistical analysis procedures as well as the signifi-
cances identified by SES confidence intervals are shown.
In this paper, when comparing haematology and clinical 
biochemistry parameters as well as relative organ weights 
between a control and a second group, the wording “sig-
nificantly different” is based on the interpretation of the 
calculated SES estimates (Fig. 1).
Stakeholder consultations
A key characteristic of GRACE is to allow for a broad involve-
ment of stakeholders and to ensure utmost transparency of the 
research process. Draft plans for diet preparation and analy-
sis as well as the study plans encompassing the conduct of 
feeding trials and the subsequent analysis described above 
were discussed with 30 stakeholder representatives (some 
500 stakeholders invited) in a two-day workshop, and writ-
ten comments were received from 16 individuals or organisa-
tions. All comments and discussions as well as the answers of 
the GRACE team members were documented in consultation 
reports and published at the project website alongside with the 
draft and revised study plans (www.grace-fp7.eu).
Results
Feed composition analysis
A detailed quantitative analysis of the different components 
of the diets used in the feeding trials A and B was performed 
(Table 4, Electronic Supplementary Material). The various 
diets showed similar levels of most of the analysed proxi-
mates (ash, total carbohydrates, fat, protein), starch, fibres, 
amino acids, fatty acids, minerals, vitamins, sugars, antinutri-
ents and secondary metabolites. In the case of the sugars, the 
11 % GMO diet in the feeding trial A contained somewhat 
higher di- and oligosaccharide (maltose, raffinose, stachyose 
and sucrose) levels and lower levels of the monosaccharides 
fructose and glucose if compared to the other diets. While 
the levels of trypsin inhibitor and the soy isoflavones daidzin 
and genistin were similar in most diets, higher levels (slightly 
above the limit of quantitation) of trypsin inhibitor in the 
33 % GMO diet in study A and higher levels of the two isofla-
vones in the 11 % GMO diet of the study A were measured.
Low and similar amounts of polychlorinated dibenzo-p-di-
oxins and dibenzofurans, polychlorinated biphenyls, poly-
cyclic aromatic hydrocarbons, mycotoxins and nitrosamines 
were detected in the ten analysed diets (Table 4, Electronic 





Fig. 1  Simplified version of a graph allowing visual assessment of 
statistical significance as well as the supposed biological and possi-
ble toxicological relevance of group comparisons. The standard effect 
size point estimate (circle) and the 95 % confidence limits (whiskers, 
bars show confidence interval) illustrate the (standardised) effect size 
between two groups. The vertical black line indicates no effect (zero 
difference), while the vertical grey lines indicate the supposed bio-
logical and possible toxicological relevance limits (here ±1.0 SD, 
according to the study design). If the confidence interval bars cross 
the zero line but not the grey lines (lie within the ±1.0 limits), there 
is evidence for no statistical significance as well as no biological rel-
evance (case a). Two groups are significantly different when the con-
fidence interval bars do not cross the black vertical line (cases b, c). 
The effect size between two groups is supposed to be biologically 
and possibly toxicologically relevant, when the confidence interval 
bars lie outside the ±1.0 SD limits (case c). Case b indicates statisti-
cal significance, but no clear biological relevance. Case d indicates no 
statistical significance, but no clear negation of biological relevance
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only fumonisin B1 in all five diets of study A, fumonisin B2 
in the 11 % GMO, 33 % GMO, conventional 1 and conven-
tional 2 diets of study A and deoxynivalenol in the conven-
tional 1 diet of study B were present in levels slightly above 
the limit of quantitation. Residues of the pesticides deltame-
thrin, ethoxyquin, piperonyl butoxide and pirimiphos-methyl 
were detected in all diets, but at levels that were considered 
not to affect the health of the rats in any way (Table 4, Elec-
tronic Supplementary Material).
As expected, the MON810 event was detected in the 
diets containing 11 and 33 % of the GM MON810 maize 
in the two feeding trials at the DNA and the protein level 
(Table 2). The diets containing the conventional maize 
varieties PR33W82 (study A) and PR32T83 (study B) 
contained very low levels of the MON810 maize event 
(Table 2), consistent with the detection of MON810 in the 
maize batches used as input material for these diets (data 
not shown). The ratio for both the MON810 event levels 
and the Cry1Ab protein contents between the diet contain-
ing 11 % GMO and the one containing 33 % GMO was 3.5 
in the study A and 2.5 in the study B (Table 2).
Following irradiation, microorganisms such as coliforms, 
Enterobacteriaceae, yeast and moulds were not detected in 
the diets (Table 4, Electronic Supplementary Material).
Feeding trial A
Body weight and feed consumption1
The body weight of the male rats in all five groups 
increased with time and reached a plateau (i.e. about 410–
430 g/rat) at week 11, whereby no statistically significant 
1
 The weight and feed consumption data were analysed by applying 
mixed models. In this context, a statistically significant difference 
means that the mixed model analysis identified a group effect.
differences in body weight were observed between the 
groups during the whole 90 days (Fig. 2a). The body 
weight of the female rats in the five experimental groups 
also increased time dependently and reached a maximum 
(about 250 g/rat) at week 11, while no statistically signifi-
cant differences in body weight were observed between the 
groups during the whole 90 days (Fig. 2b).
Feed consumption in male rats increased in the first 
3 weeks, remained relatively constant until week 9 and 
slightly decreased thereafter (Fig. 3a). Males being fed the 
11 % GMO diet consumed significantly less than the males 
in the control and the 33 % GMO groups. In the case of the 
female rats, feed consumption remained constant through-
out the feeding trial except for a decrease at week 11 
(Fig. 3b). The decrease in feed consumption went in paral-
lel with a defect of the air conditioning system in the ani-
mal housing facility that led to a temperature of 30–32 °C 
in the animal rooms for a 1-week period. Female animals 
fed the 11 % GMO diet consumed significantly less than 
the groups being fed the control diet.
Feed consumption in male and female rats fed the con-
ventional 1 diet was similar to that of male and female ani-
mals fed the control diet, while feed consumption in male 
and female rats fed the conventional 2 diet was signifi-
cantly lower than that of male and female animals fed the 
control diet (Fig. 3a, b).
Clinical and ophthalmological observations
No signs of morbidity and mortality were observed 
throughout the 90-day feeding period, and the daily clini-
cal observations did not reveal any signs of functional defi-
cits. The ophthalmological analyses revealed individual 
alterations in all five experimental groups in the first week, 
whereas no alterations were visible in the 12th week of the 
feeding trial (Table 5, Electronic Supplementary Material).
Table 2  Cry1Ab levels the different diets used in the rat feeding trials A and B
n.q. not quantifiable
Study A Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % DKC6666 11 % DKC6667-YG  
+ 22 % DKC6666
33 % DKC6667-YG 33 % PR33W82 33 % SY-NEPAL
MON810 maize event—genetically 
modified DNA (%)
Detected, n.q. 14.6 50.8 1.2 Not detected
Cry1Ab (ng/mg protein) Not detected 0.77 2.83 0.05 Not detected
Study B Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % PR32T16 11 % PR33D48  
+ 22 % PR32T16
33 % PR33D48 33 % PR32T83 33 % DKC6815
MON810 maize event—genetically 
modified DNA (%)
Not detected 18.9 47.6 2.6 Not detected
Cry1Ab (ng/mg protein) Not detected 2.01 5.15 0.18 Not detected
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Haematology and clinical biochemistry analyses2
The haematology parameters measured in the blood sam-
ples of male and female rats are shown in Table 3 and the 
corresponding SES graphs in Figs. 4 and 5. The haema-
tology parameters WBC, RBC, HGB, HCT, MCV, MCH, 
MCHC, PLT and LYM were similar in the control, 11 % 
2
 For all the haematology and clinical biochemistry endpoints as well 
as for the relative organ weights, SES was calculated. In this context, 
a statistically significant difference means that the confidence inter-
val of the SES to the control does not include the zero value, while 
“similar” means that the confidence interval of the SES to the control 
includes the zero value (Fig. 1).
GMO and 33 % GMO groups, this being the case of male 
as well as female rats (Table 3). The differential leucocyte 
count showed that the percentage of lymphocytes in male 
rats fed the 33 % GMO diet was significantly lower and the 
percentage of eosinophils significantly higher than in male 
rats fed the control diet (Table 3; Fig. 4b), while in female 
rats fed the 11 % GMO diet the percentage of monocytes 
was significantly higher than in the animals fed the control 
diet (Table 3; Fig. 5a).
The haematology parameters and the differential leu-
cocyte count were similar in male and female rats fed 
the control, conventional 1 and conventional 2 diets with 





































Fig. 2  Male and female rat body weights in the feeding trial A. The data represent the mean body weight ± standard deviation of 16 male (a) 
and 16 female rats (b) in the feeding trial A. Asterisk Week 13 = 5 days
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significantly lower and the percentage of monocytes was 
significantly higher in female rats fed the conventional 2 
diet when compared to the corresponding animals fed the 
control diet (Table 3; Fig. 5d).
The clinical biochemistry parameters measured in 
serum of male and female rats are shown in Table 4 and 
the corresponding SES graphs in Figs. 4 and 5. Regard-
ing male rats, TP levels were significantly lower in the 
animals fed the 11 % GMO and 33 % GMO diets than in 
those fed the control diet, whereas GLU, CHOL, TRG, 
Cl, Na and P levels were significantly higher in the ani-
mals fed the 11 % GMO and 33 % GMO diets than in 
those fed the control diet (Table 4; Fig. 4a, b). Moreover, 
male animals fed the 33 % GMO diet showed signifi-
cantly higher K levels. In female rats fed the 11 % GMO 
diet, ALP and ALT activities as well as Na levels were 
significantly higher, while in female animals fed the 
33 % GMO diet ALP activity and U levels were signifi-
cantly higher than in those fed the control diet (Table 4; 
Fig. 5a, b).
All clinical biochemistry parameters measured in male 
and female rats fed the control, conventional 1 and conven-
tional 2 diets were similar with one exception: TRG levels 
were significantly higher in male rats fed the conventional 
1 and the conventional 2 diets when compared to the cor-
responding control group (Table 4).






























































Fig. 3  Male and female rat feed consumption in the feeding trial A. The data represent the weekly feed consumption per cage ± standard devia-
tion for male (a) and female rats (b) in the feeding trial A. Asterisk Week 13 = 5 days
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Gross necropsy, absolute and relative organ weights 
and histopathology2,3
Gross lesions were observed in two out of 16 male rats 
having been fed the 11 % GMO, the conventional 1 or 
the conventional 2 diet and in 3 out of 16 female rats in 
each of the five experimental groups (Table 6, Electronic 
3
 Slides of all tissues analysed may be looked at on request at the 
Laboratory of Toxicology of the Slovak Medical University (Brati-
slava, Slovakia).
Supplementary Material). The subsequent histopathologi-
cal analysis of all gross lesions revealed that a papillary 
carcinoma of the mammary gland had developed in one 
female rat fed the conventional 2 diet (Table 6, Electronic 
Supplementary Material).
The absolute weight of the pancreas in male rats fed the 
11 % GMO diet was significantly lower than in the con-
trol rats, whereas the absolute weight of the left adrenal 
gland was significantly higher and the absolute weight of 
the pancreas as well as the brain was significantly lower in 
male rats fed the 33 % GMO diet than in the control male 
Table 3  Haematology parameters (cage mean ± SD) of male and female Wistar Han RCC rats in the feeding trial A
WBC white blood cells, RBC red blood cells, HGB haemoglobin, HCT haematocrit, MCV mean cell volume, MCH mean corpuscular haemoglo-
bin, MCHC mean corpuscular haemoglobin concentration, PLT platelets, LYM lymphocytes
a
 Statistically significant difference to control group based on one-way ANOVA, post hoc t test (p < 0.01), post hoc Dunnett test (p < 0.05)
(a)
 Statistically significant difference to control group (p < 0.05) based on one-way ANOVA and post hoc t test, post hoc Dunnett test not signifi-
cant
b
 Statistically significant difference to control group (p < 0.05) based on the Wilcoxon test
c
 Statistically significant difference to control group based on the 95 % confidence interval of the SES
Parameter Number  
of animals
Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % DKC6666 11 % DKC6667-YG  
+ 22 % DKC6666
33 % DKC6667-YG 33 % PR33W82 33 % SY-NEPAL
Male rats
 WBC (103/µl) 16 11.64 ± 2.44 11.41 ± 2.08 13.35 ± 2.59 11.99 ± 3.29 10.98 ± 2.51
 RBC (106/µl) 16 8.38 ± 0.55 8.33 ± 0.30 8.64 ± 0.19 8.06 ± 0.55 8.15 ± 0.61
 HGB (g/dl) 16 15.93 ± 1.66 16.06 ± 0.95 16.33 ± 0.49 15.76 ± 0.94 15.76 ± 1.03
 HCT (%) 16 46.61 ± 2.62 45.86 ± 1.96 47.48 ± 1.25 44.75 ± 3.10 45.32 ± 3.27
 MCV (fl) 16 55.74 ± 1.43 55.08 ± 0.50 54.99 ± 1.42 55.56 ± 1.11 55.67 ± 0.93
 MCH (pg) 16 19.01 ± 1.27 19.30 ± 0.50 18.91 ± 0.71 19.61 ± 0.52(a) 19.39 ± 0.60
 MCHC (g/dl) 16 34.11 ± 2.01 35.03 ± 0.76 34.40 ± 0.60 35.27 ± 0.72 34.83 ± 0.87
 PLT (103/µl) 16 655.81 ± 243.12 686.19 ± 127.80 660.00 ± 183.97 617.81 ± 161.73 643.31 ± 160.55
 LYM (103/µl) 16 9.43 ± 2.27 9.33 ± 1.76 10.36 ± 1.65 9.44 ± 2.50 8.81 ± 1.91
 Lymphocytes (%) 16 81.13 ± 2.44 79.28 ± 1.61 77.09 ± 4.02a,b,c 78.53 ± 2.43 80.31 ± 2.66
 Neutrophils (%) 16 14.03 ± 2.52 15.13 ± 1.17 16.22 ± 3.25 16.03 ± 2.15 14.88 ± 2.61
 Monocytes (%) 16 3.47 ± 1.22 4.06 ± 0.84 4.09 ± 0.92 3.44 ± 1.10 3.59 ± 0.55
 Eosinophils (%) 16 1.34 ± 0.61 1.53 ± 0.56 2.56 ± 1.03a,b,c 1.94 ± 0.51 1.22 ± 0.66
Female rats
 WBC (103/µl) 16 8.85 ± 2.15 8.34 ± 1.50 10.57 ± 1.49 7.72 ± 1.61 9.08 ± 2.92
 RBC (106/µl) 16 7.66 ± 0.32 7.48 ± 0.39 7.52 ± 0.21 7.54 ± 0.18 7.45 ± 0.17
 HGB (g/dl) 16 15.39 ± 0.40 15.23 ± 0.55 15.31 ± 0.40 15.39 ± 0.58 15.18 ± 0.36
 HCT (%) 16 43.69 ± 1.20 43.20 ± 1.85 42.91 ± 1.39 43.15 ± 1.05 42.94 ± 1.19
 MCV (fl) 16 57.11 ± 1.45 57.75 ± 0.93 57.09 ± 0.89 57.24 ± 0.92 57.66 ± 1.66
 MCH (pg) 16 20.11 ± 0.63 20.38 ± 0.48 20.36 ± 0.29 20.44 ± 0.83 20.38 ± 0.65
 MCHC (g/dl) 16 35.24 ± 0.48 35.29 ± 0.49 35.68 ± 0.38 35.68 ± 1.16 35.35 ± 0.52
 PLT (103/µl) 16 844.81 ± 72.75 860.38 ± 65.43 810.56 ± 81.53 703.44 ± 180.28(a) 825.63 ± 68.32
 LYM (103/µl) 16 7.26 ± 1.67 6.76 ± 1.52 8.55 ± 1.14 6.26 ± 1.41 7.43 ± 2.51
 Lymphocytes (%) 16 82.88 ± 2.65 80.31 ± 2.73 80.97 ± 4.52 80.16 ± 3.89 79.91 ± 2.09b,c
 Neutrophils (%) 16 13.44 ± 2.84 14.97 ± 2.43 14.75 ± 4.42 15.28 ± 2.48 15.03 ± 1.38
 Monocytes (%) 16 2.19 ± 0.42 2.84 ± 0.33b,c 2.94 ± 1.02 3.00 ± 1.17 3.06 ± 0.79(a),b,c
 Eosinophils (%) 16 1.50 ± 0.76 1.88 ± 0.67 1.34 ± 0.60 1.53 ± 1.02 2.00 ± 0.65b
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Trial A, sex: male, comparison: control - conventional 2, analysis: cage means(C) (D)
Fig. 4  Standardised effect size graphs for the comparison of the haematology, clinical biochemistry and organ weight data between the control 
and the 11 % GMO (a), 33 % GMO (b), conventional 1 (c) or conventional 2 groups (d) in the case of male rats in feeding trial A




Fig. 5  Standardised effect size graphs for the comparison of the haematology, clinical biochemistry and organ weight data between the control 
and the 11 % GMO (a), 33 % GMO (b), conventional 1 (c) or conventional 2 groups (d) in the case of female rats in feeding trial A
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animals (Table 7, Electronic Supplementary Material). In 
female rats fed the 33 % GMO diet, the absolute weight of 
the lung was significantly lower than in control female rats 
(Table 7, Electronic Supplementary Material). The absolute 
weight of all other organs was similar in male and female 
animals fed the control, 11 % GMO and 33 % GMO diets.
The absolute weight of the pancreas was significantly 
lower in male rats fed the conventional 2 diet than in those 
fed the control diet (Table 7, Electronic Supplementary 
Material), while the absolute weight of all other organs was 
similar in male and female animals fed the control, conven-
tional 1 and conventional 2 diets.
Table 4  Clinical biochemistry parameters (cage mean ± SD) in the serum of male and female Wistar Han RCC rats in the feeding trial A
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TP total protein, GLU glucose, CREA 
creatinine, U urea, CHOL cholesterol, TRG triglycerides, Ca calcium, Cl chloride, K potassium, Na sodium, P phosphorus. Except where indi-
cated (* n = 15; ** n = 14), the number of analysed rats was 16
a
 Statistically significant difference to the control value based on one-way ANOVA and post hoc t test (p ≤ 0.01) as well as with the Dunnett test 
(p ≤ 0.05)
(a)
 Statistically significant difference to the control value (p < 0.05) based on one-way ANOVA and post hoc t test, but not with the Dunnett test
b
 Statistically significant difference to the control value (p < 0.05) based on the Wilcoxon test
c
 Statistically significant difference to the control value based on the 95 % confidence interval of the SES
Parameter Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % DKC6666 11 % DKC6667-YG  
+ 22 % DKC6666
33 % DKC6667-YG 33 % PR33W82 33 % SY-NEPAL
Male rats
 ALP (µkat/l) 1.30 ± 0.25 1.49 ± 0.14 1.42 ± 0.14 1.38 ± 0.37 1.53 ± 0.34*
 ALT (µkat/l) 0.53 ± 0.05 0.53 ± 0.04 0.53 ± 0.04 0.51 ± 0.06 1.22 ± 1.93*
 AST (µkat/l) 1.22 ± 0.27 1.17 ± 0.12 1.36 ± 0.19 1.11 ± 0.18 1.84 ± 1.77*
 ALB (g/l) 32.49 ± 2.82 31.72 ± 1.77 30.14 ± 1.38(a),b 31.78 ± 1.69 32.41 ± 2.71*
 TP (g/l) 61.49 ± 3.24 57.02 ± 2.61a,b,c 54.74 ± 3.97a,b,c 60.77 ± 3.18 59.79 ± 2.81*
 GLU (mmol/l) 8.47 ± 0.90 10.80 ± 1.22a,b,c 10.83 ± 1.19a,b,c 9.75 ± 1.40 9.52 ± 1.63*
 CREA (µmol/l) 40.49 ± 4.44 37.28 ± 0.97 36.82 ± 1.59 38.80 ± 4.32 39.37 ± 7.15*
 U (mmol/l) 6.08 ± 0.35 6.14 ± 0.42 6.44 ± 0.58 5.93 ± 0.44 6.48 ± 0.45*
 CHOL (mmol/l) 2.19 ± 0.32 2.74 ± 0.52a,b,c 2.69 ± 0.48(a),b,c 2.47 ± 0.27 2.52 ± 0.36*
 TRG (mmol/l) 0.49 ± 0.12 0.75 ± 0.27a,b,c 0.82 ± 0.16a,b,c 0.71 ± 0.16(a),b,c 0.75 ± 0.20*,a,b,c
 Ca (mmol/l) 2.71 ± 0.12 2.67 ± 0.31 3.01 ± 0.39(a),b 2.70 ± 0.19 2.77 ± 0.14*
 Cl (mmol/l) 109.50 ± 3.70 124.13 ± 15.93(a),b,c 122.06 ± 13.01(a),b,c 110.38 ± 4.44 115.56 ± 15.08*
 K (mmol/l) 4.78 ± 0.50 5.21 ± 0.93 5.58 ± 0.76b,c 4.89 ± 0.54 5.23 ± 1.16**
 Na (mmol/l) 150.38 ± 4.73 174.31 ± 23.66a,b,c 168.94 ± 20.28(a),c 151.00 ± 7.76 161.00 ± 23.40*
 P (mmol/l) 2.67 ± 0.25 3.23 ± 0.44(a),b,c 3.15 ± 0.37(a),b,c 2.72 ± 0.24 3.15 ± 0.70*,(a),b
Female rats
 ALP (µkat/l) 0.59 ± 0.08 0.86 ± 0.20a,b,c 0.83 ± 0.17*,a,b,c 0.59 ± 0.11 0.62 ± 0.09*
 ALT (µkat/l) 0.45 ± 0.04 0.54 ± 0.10c 0.46 ± 0.04* 0.53 ± 0.15 0.46 ± 0.09*
 AST (µkat/l) 0.96 ± 0.16 1.09 ± 0.13 1.19 ± 0.25* 1.27 ± 0.73 1.02 ± 0.15*
 ALB (g/l) 41.19 ± 4.49 43.14 ± 4.93 43.71 ± 3.58* 41.30 ± 4.57 42.43 ± 3.98*
 TP (g/l) 69.12 ± 5.90 69.52 ± 4.56 69.27 ± 4.46* 67.49 ± 5.22 68.13 ± 4.61*
 GLU (mmol/l) 7.41 ± 1.22 8.05 ± 1.11 7.79 ± 1.38* 6.99 ± 1.58 8.40 ± 0.96*
 CREA (µmol/l) 35.64 ± 3.07 37.79 ± 3.24 38.31 ± 5.40* 42.65 ± 8.66a 37.81 ± 2.74*
 U (mmol/l) 5.17 ± 0.35 5.46 ± 0.42 5.72 ± 0.53*,c 5.83 ± 0.80(a) 5.55 ± 0.59*
 CHOL (mmol/l) 2.14 ± 0.35 2.29 ± 0.44 2.20 ± 0.40* 2.07 ± 0.14* 2.35 ± 0.23*
 TRG (mmol/l) 0.56 ± 0.14* 0.49 ± 0.11 0.42 ± 0.14*,(a) 0.48 ± 0.10* 0.48 ± 0.08*
 Ca (mmol/l) 2.82 ± 0.05* 2.84 ± 0.08 2.76 ± 0.11* 2.82 ± 0.10** 2.85 ± 0.13*
 Cl (mmol/l) 108.69 ± 4.29 113.25 ± 3.85(a) 108.44 ± 3.73* 110.13 ± 3.89 109.44 ± 4.84*
 K (mmol/l) 4.04 ± 0.15* 4.18 ± 0.34 3.94 ± 0.46* 4.54 ± 1.68* 3.96 ± 0.14*
 Na (mmol/l) 149.25 ± 4.40* 156.19 ± 3.59a,b,c 149.94 ± 3.48* 152.36 ± 6.66** 150.25 ± 5.82*
 P (mmol/l) 2.49 ± 0.20* 2.64 ± 0.28 2.26 ± 0.25* 2.76 ± 0.38** 2.47 ± 0.29*
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The relative liver weight was significantly higher, and the 
relative pancreas weight was significantly lower in male rats 
fed the 11 and 33 % GMO diet (Table 5; Fig. 4a, b). In male 
animals fed the 33 % GMO diet, the relative weight of the 
left adrenal gland was significantly higher when compared 
to that of control male rats (Table 5; Fig. 4b). The relative 
weight of all other organs was similar in male and female 
animals fed the control, 11 % GMO and 33 % GMO diets.
The relative weight of all organs was similar in male and 
female rats fed the control, conventional 1 and conventional 
2 diets, except for the relative weight of the thymus, which 
was significantly lower in female rats fed the conventional 
diet 1 if compared to the control female animals (Table 5; 
Fig. 5c).
Histological changes were sporadically observed in 
the control and 33 % GMO group (Table 6). Since no 
Table 5  Relative weight of the organs (cage mean ± SD) of male and female Wistar Han RCC rats in the feeding trial A
a
 Statistically significant difference to control group based on one-way ANOVA, post hoc t test (p < 0.01), post hoc Dunnett test (p < 0.05)
(a)
 Statistically significant difference to control group (p < 0.05) based on one-way ANOVA and post hoc t test, post hoc Dunnett test not signifi-
cant
b
 Statistically significant difference to control group (p < 0.05) based on the Wilcoxon test
c
 Statistically significant difference to control group based on the 95 % confidence interval of the SES
Organ Number of 
animals
Relative organ weights (organ weight/body weight × 100)
Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % DKC6666 11 % DKC6667-YG  
+ 22 % DKC6666
33 % DKC6667-YG 33 % PR33W82 33 % SY-NEPAL
Male rats
 Kidney (right) 16 0.275 ± 0.020 0.274 ± 0.017 0.285 ± 0.023 0.269 ± 0.017 0.277 ± 0.016
 Kidney (left) 16 0.288 ± 0.014 0.287 ± 0.013 0.286 ± 0.020 0.281 ± 0.013 0.287 ± 0.014
 Spleen 16 0.187 ± 0.021 0.176 ± 0.020 0.178 ± 0.014 0.177 ± 0.015 0.189 ± 0.013
 Liver 16 2.127 ± 0.072 2.258 ± 0.120(a),b,c 2.253 ± 0.083(a),b,c 2.192 ± 0.103 2.251 ± 0.179(a)
 Adrenal gland (right) 16 0.006 ± 0.001 0.007 ± 0.001 0.007 ± 0.001 0.006 ± 0.001 0.007 ± 0.001
 Adrenal gland (left) 16 0.006 ± 0.000 0.007 ± 0.001 0.007 ± 0.001(a),b,c 0.007 ± 0.001 0.007 ± 0.001
 Lung 16 0.357 ± 0.028 0.344 ± 0.044 0.359 ± 0.027 0.343 ± 0.023 0.353 ± 0.040
 Heart 16 0.242 ± 0.014 0.232 ± 0.012 0.239 ± 0.015 0.229 ± 0.012(a) 0.233 ± 0.014
 Thymus 16 0.096 ± 0.016 0.111 ± 0.020 0.109 ± 0.027 0.091 ± 0.010 0.090 ± 0.021
 Pancreas 16 0.141 ± 0.016 0.115 ± 0.016a,b,c 0.112 ± 0.009a,b,c 0.134 ± 0.026 0.121 ± 0.022(a)
 Testis (right) 16 0.476 ± 0.050 0.452 ± 0.022 0.452 ± 0.018 0.452 ± 0.028 0.478 ± 0.034
 Testis (left) 16 0.474 ± 0.055 0.454 ± 0.023 0.453 ± 0.026 0.455 ± 0.029 0.479 ± 0.034
 Epididymis (right) 16 0.157 ± 0.016 0.157 ± 0.007 0.156 ± 0.009 0.151 ± 0.012 0.156 ± 0.016
 Epididymis (left) 16 0.159 ± 0.017 0.159 ± 0.008 0.159 ± 0.008 0.156 ± 0.014 0.156 ± 0.014
 Brain 16 0.527 ± 0.025 0.524 ± 0.019 0.509 ± 0.025 0.516 ± 0.028 0.549 ± 0.031
Female rats
 Kidney (right) 16 0.318 ± 0.015 0.314 ± 0.026 0.323 ± 0.017 0.309 ± 0.018 0.317 ± 0.014
 Kidney (left) 16 0.319 ± 0.017 0.327 ± 0.026 0.332 ± 0.015 0.320 ± 0.017 0.323 ± 0.017
 Spleen 16 0.249 ± 0.018 0.243 ± 0.015 0.243 ± 0.018 0.247 ± 0.025 0.241 ± 0.022
 Liver 16 2.494 ± 0.113 2.525 ± 0.102 2.523 ± 0.084 2.536 ± 0.190 2.646 ± 0.162(a)
 Adrenal gland (right) 16 0.014 ± 0.001 0.015 ± 0.003 0.015 ± 0.001 0.014 ± 0.003 0.014 ± 0.001
 Adrenal gland (left) 16 0.015 ± 0.001 0.014 ± 0.002 0.016 ± 0.002 0.015 ± 0.001 0.015 ± 0.001
 Lung 16 0.472 ± 0.037 0.466 ± 0.036 0.453 ± 0.018 0.461 ± 0.034 0.461 ± 0.028
 Heart 16 0.293 ± 0.019 0.293 ± 0.013 0.288 ± 0.026 0.291 ± 0.017 0.299 ± 0.022
 Thymus 16 0.132 ± 0.019 0.144 ± 0.019 0.148 ± 0.021 0.114 ± 0.007(a),b,c 0.135 ± 0.019
 Pancreas 16 0.182 ± 0.021 0.198 ± 0.030 0.199 ± 0.028 0.189 ± 0.020 0.203 ± 0.026
 Uterus 16 0.209 ± 0.021 0.223 ± 0.037 0.213 ± 0.035 0.226 ± 0.032 0.215 ± 0.028
 Ovary (right) 16 0.026 ± 0.004 0.028 ± 0.006 0.027 ± 0.004 0.028 ± 0.002 0.028 ± 0.002
 Ovary (left) 16 0.026 ± 0.005 0.028 ± 0.005 0.028 ± 0.005 0.028 ± 0.002 0.030 ± 0.004
 Brain 16 0.805 ± 0.077 0.809 ± 0.049 0.828 ± 0.045 0.823 ± 0.019 0.821 ± 0.054
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treatment-related changes were observed between the two 
groups, no further tissue analyses were carried out on other 
groups.
Feeding trial B
Body weight and feed consumption1
The body weight of the male rats in all five groups 
increased with time and reached a plateau (i.e. about 410–
430 g/rat) in the 12th week, whereby no statistically sig-
nificant differences in body weight were observed between 
the groups at any time during the whole 90 days (Fig. 6a). 
The body weight of the female rats in the five experimen-
tal groups also increased time dependently and reached a 
maximum (about 240–250 g/rat) at the end of the feeding 
period, while no statistically significant differences in body 
weight were observed between the groups at any time dur-
ing the whole 90 days (Fig. 6b).
In the case of male rats, feed consumption gradually 
increased in the first 3 weeks, decreased between week 8 
and week 10 and slightly increased thereafter (Fig. 7a). 
Feed consumption in the female rats showed a stepwise 
increase until the fourth week, decreased in week nine and 
then increased until the end of the feeding period (Fig. 7b). 
No statistically significant differences in feed consumption 
were observed between the male and female rats in the five 
experimental groups. As in the case of the feeding trial A, 
the decrease in feed consumption went in parallel with a 
defect of the air conditioning system in the animal housing 
facility that led to a temperature of 30–32 °C in the animal 
rooms for a 1-week period.
Clinical and ophthalmological observations
No signs of morbidity and mortality were observed 
throughout the 90-day feeding period. At the end of the 
feeding trial, one male rat fed the conventional 2 diet had 
overgrown front teeth and one female rat fed the control 
diet had a hairless area behind the left ear, while the daily 
clinical observations did not reveal any signs of functional 
deficits. The ophthalmological analyses revealed that indi-
vidual alterations were observed in all five experimental 
groups in the first week, while only one animal, a male rat 
fed the 11 % GMO diet, with an haemorrhage was observed 
in the 12th week of the feeding trial (Table 5, Electronic 
Supplementary Material).
Haematology and clinical biochemistry analyses2
The haematology parameters of male and female rats are 
shown in Table 7 and the corresponding SES graphs in 
Figs. 8 and 9. In male rats fed the 11 % GMO diet, RBC 
and HCT were significantly higher, while MCHC and the 
percentage of monocytes were significantly lower than in 
male rats fed the control diet (Table 7; Fig. 8a). In male rats 
fed the 33 % GMO diet, WBC and LYM were significantly 
higher, while MCHC and the percentage of monocytes 
were significantly lower than in male rats fed the control 
diet (Table 7; Fig. 8b). In the case of female rats, the group 
being fed the 11 % GMO diet had a significantly higher 
RBC and HCT and significantly lower MCH and MCHC 
than the control group (Table 7; Fig. 9a). The female rats 
being fed the 33 % GMO diet had significantly higher 
WBC, RBC, LYM as well as monocyte percentage and sig-
nificantly lower MCV and neutrophil percentage than the 
control group (Table 7; Fig. 9b).
Male rats fed the conventional 1 diet had a significantly 
lower percentage of monocytes than the male animals fed 
the control diet (Table 7; Fig. 8c), while no statistically 
significant differences regarding the haematology param-
eters were observed between the female rats fed the con-
ventional 1 and the control diet. Male rats fed the conven-
tional 2 diet had significantly higher WBC, PLT and LYM 
and a significantly lower percentage of monocytes than the 
Table 6  Histological findings 
in male and female Wistar Han 
RCC rats set in the feeding 
trial A
Organ Histological finding 33 % near-isogenic 
non-GM maize
33 % MON810 
maize
Males
 Prostate Focal fibrosis 1/16 0/16
Interstitial mononuclear infiltration 2/16 2/16
 Seminal vesicles Interstitial mononuclear infiltration 0/16 2/16
Females
 Kidney Cysts 1/16 0/16
 Ovary Cystic follicles 0/16 1/16
 Small intestine Lymphoepithelioid granuloma 2/16 1/16
 Uterus Calcified lymph nodes 0/16 1/16
Mucification of the endometrial  
epithelium
1/16 0/16
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male animals fed the control diet (Table 7; Fig. 8d), while 
female rats fed the conventional 2 diet had a significantly 
lower MCV than the female animals in the control group 
(Table 7; Fig. 9d).
The clinical biochemistry parameters of male and female 
rats are shown in Table 8 and the corresponding SES 
graphs in Figs. 8 and 9. In male rats fed the 11 % GMO 
diet U, Ca and P levels were significantly higher and the 
Na level was significantly lower than in the control group 
(Table 8; Fig. 8a). In male rats fed the 33 % GMO diet, 
U and Ca levels were significantly higher and the Na level 
was significantly lower than in the control group (Table 8; 
Fig. 8b). In the case of the female rats, U and Ca levels 
were significantly higher in the 11 % GMO group when 
compared to the control group (Table 8; Fig. 9a). In female 
rats fed the 33 % GMO diet ALT, AST and Ca levels were 
significantly higher and those of TP and Na significantly 
were lower than in the rats fed the control diet (Table 8; 
Fig. 9b).
The U level was significantly higher in male rats fed 
the conventional 1 diet, while the U level was significantly 
higher and the Cl level significantly lower in male rats fed 
the conventional 2 diet if compared to the corresponding 
control group (Table 8; Fig. 8c, d). In the case of female 
rats fed the conventional 1 diet, Ca levels were significantly 





































Fig. 6  Male and female rat body weights in the feeding trial B. The data represent the mean body weight ± standard deviation of 16 male (a) 
and 16 female rats (b) in the feeding trial B. Asterisk Week 13 = 5 days
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the conventional 2 diet TP and Na levels were significantly 
lower and the U level significantly higher than in rats fed 
the control diet (Table 8; Fig. 9c, d).
Gross necropsy, absolute and relative organ weights 
and histopathology2,3
Gross lesions were observed in 1–3 out of 16 male rats hav-
ing been fed the control, the 11 % GMO, the 33 % GMO 
or the conventional 2 diet and in 1–4 out of 16 female rats 
having been fed the 11 % GMO, the 33 % GMO or the con-
ventional 2 diet (Table 6, Electronic Supplementary Mate-
rial). The subsequent histopathological analysis of all gross 
lesions revealed that a lipoma had developed in one female 
rat fed the 33 % GMO diet (Table 6, Electronic Supple-
mentary Material).
The absolute weight of the kidneys, spleen, liver, 
adrenal glands, lung, heart, thymus, pancreas, testes, 
epididymides and brain in the male rats of all five exper-
imental groups were similar, except for the absolute lung 
weight in the 11 % GMO and the conventional 2 groups, 
which was significantly higher than that in the control 
group (Table 7, Electronic Supplementary Material). In 
the case of the female rats, the absolute pancreas weight 
was significantly lower in the conventional 1 group, 
while the absolute thymus weight in 33 % GMO-fed 
animals and the absolute weight of the left ovary in the 

























































Fig. 7  Male and female rat feed consumption in the feeding trial B. The data represent the weekly feed consumption per cage ± standard devia-
tion for male (a) and female rats (b) in the feeding trial B. Asterisk Week 13 = 5 days
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compared to the control group (Table 7, Electronic Sup-
plementary Material). The absolute weight of all other 
organs was similar in the five experimental groups.
The relative weight of the lung was significantly higher 
in male rats fed the 11 % GMO and conventional 2 diets 
(Table 9; Fig. 8a, d). Furthermore, the relative weight of 
the thymus was significantly higher in female rats fed the 
11 % GMO and the 33 % GMO diets, while the relative 
weight of the left ovary was significantly higher in female 
rats fed the conventional 2 diet than in the control female 
animals (Table 9; Fig. 9a, b, d). The relative weight of all 
other organs was similar in the five experimental groups.
Histological changes were sporadically observed in the 
control and 33 % GMO group (Table 10). In one out of 16 
female 33 % GMO-fed rats, a mesenteric lipoma was diag-
nosed. Since no treatment-related changes were observed 
between the two groups, no further tissue analyses were 
carried out.
Table 7  Haematology parameters (cage mean ± SD) of male and female Wistar Han RCC rats in the feeding trial B
WBC white blood cells, RBC red blood cells, HGB haemoglobin, HCT haematocrit, MCV mean cell volume, MCH mean corpuscular haemoglo-
bin, MCHC mean corpuscular haemoglobin concentration, PLT platelets, LYM lymphocytes
a
 Statistically significant difference to control group based on one-way ANOVA, post hoc t test (p < 0.01), post hoc Dunnett test (p < 0.05)
(a)
 Statistically significant difference to control group (p < 0.05) based on one-way ANOVA and post hoc t test, post hoc Dunnett test not signifi-
cant
b
 Statistically significant difference to control group (p < 0.05) based on Wilcoxon test
c
 Statistically significant difference to control group based on 95 % confidence interval of the SES
Parameter Number  
of animals
Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % PR32T16 11 % PR33D48 +  
22 % PR32T16
33 % PR33D48 33 % PR32T83 33 % DKC6815
Male rats
 WBC (103/µl) 16 9.44 ± 1.67 10.57 ± 1.53 12.12 ± 1.95(a),b,c 10.04 ± 2.60 12.91 ± 2.70a,b,c
 RBC (106/µl) 16 8.50 ± 0.23 8.86 ± 0.29a,b,c 8.82 ± 0.37(a),b 8.46 ± 0.15 8.55 ± 0.30
 HGB (g/dl) 16 16.39 ± 0.32 16.69 ± 0.45 16.61 ± 0.55 16.43 ± 0.49 16.48 ± 0.41
 HCT (%) 16 47.21 ± 1.09 49.04 ± 1.41a,b,c 48.76 ± 2.00(a) 47.06 ± 1.21 47.55 ± 1.22
 MCV (fl) 16 55.60 ± 0.73 55.38 ± 1.22 55.27 ± 0.82 55.61 ± 0.78 55.66 ± 1.02
 MCH (pg) 16 19.31 ± 0.39 18.85 ± 0.63 18.84 ± 0.59 19.43 ± 0.46 19.30 ± 0.35
 MCHC (g/dl) 16 34.73 ± 0.38 34.04 ± 0.53a,b,c 34.08 ± 0.66a,c 34.91 ± 0.43 34.64 ± 0.17
 PLT (103/µl) 16 838.13 ± 60.16 844.06 ± 68.74 862.19 ± 74.94 874.44 ± 51.34 921.13 ± 52.71a,b,c
 LYM (103/µl) 16 8.17 ± 1.38 8.69 ± 1.32 9.88 ± 1.50(a),b,c 8.35 ± 1.95 10.50 ± 1.23a,b,c
 Lymphocytes (%) 16 78.66 ± 2.44 79.25 ± 3.75 80.72 ± 2.26 79.44 ± 3.50 80.06 ± 3.60
 Neutrophils (%) 16 14.91 ± 1.81 15.63 ± 3.79 14.47 ± 1.88 15.00 ± 3.32 14.97 ± 2.43
 Monocytes (%) 16 4.81 ± 0.98 3.13 ± 0.64a,b,c 3.50 ± 1.13a,b,c 3.81 ± 0.73(a),b,c 3.06 ± 0.78a,b,c
 Eosinophils (%) 16 1.59 ± 0.72 1.97 ± 0.99 1.31 ± 0.65 1.75 ± 1.15 1.91 ± 0.76
Female rats
 WBC (103/µl) 16 8.78 ± 1.77 7.59 ± 1.24 10.52 ± 1.10(a),b,c 7.12 ± 1.94(a) 7.98 ± 0.83
 RBC (106/µl) 16 7.61 ± 0.30 7.95 ± 0.30(a),c 7.92 ± 0.25(a),b,c 7.55 ± 0.24 7.86 ± 0.28
 HGB (g/dl) 16 15.55 ± 0.38 15.62 ± 0.23 15.68 ± 0.36 15.30 ± 0.24 15.74 ± 0.42
 HCT (%) 16 44.06 ± 1.16 45.34 ± 1.02(a),b,c 44.93 ± 0.92 43.41 ± 0.89 44.86 ± 1.26
 MCV (fl) 16 57.93 ± 0.88 57.05 ± 1.18 56.75 ± 1.02(a),b,c 57.58 ± 0.92 57.07 ± 0.52b,c
 MCH (pg) 16 20.46 ± 0.51 19.68 ± 0.70a,c 19.81 ± 0.68(a) 20.30 ± 0.48 20.03 ± 0.44
 MCHC (g/dl) 16 35.29 ± 0.61 34.48 ± 0.57a,b,c 34.89 ± 0.71 35.26 ± 0.61 35.09 ± 0.56
 PLT (103/µl) 16 841.44 ± 75.50 812.31 ± 83.43 763.13 ± 139.54 817.44 ± 146.20 833.25 ± 147.17
 LYM (103/µl) 16 6.89 ± 1.32 5.99 ± 0.94 8.59 ± 1.00(a),b,c 5.81 ± 1.47 6.36 ± 0.82
 Lymphocytes (%) 16 82.25 ± 2.30 82.91 ± 3.10 83.56 ± 2.61 80.59 ± 2.07 81.97 ± 3.21
 Neutrophils (%) 16 14.31 ± 1.81 13.03 ± 2.82 11.38 ± 2.93(a),c 15.50 ± 2.00 13.22 ± 3.48
 Monocytes (%) 16 2.03 ± 0.43 2.66 ± 1.08 3.53 ± 1.19a,b,c 2.34 ± 0.80 2.94 ± 1.08b
 Eosinophils (%) 16 1.41 ± 0.52 1.38 ± 0.50 1.53 ± 0.41 1.53 ± 0.36 1.88 ± 0.40(a)




Fig. 8  Standardised effect size graphs for the comparison of the haematology, clinical biochemistry and organ weight data between the control 
and the 11 % GMO (a), 33 % GMO (b), conventional 1 (c) or conventional 2 groups (d) in the case of male rats in feeding trial B




Fig. 9  Standardised effect size graphs for the comparison of the haematology, clinical biochemistry and organ weight data between the control 
and the 11 % GMO (a), 33 % GMO (b), conventional 1 (c) or conventional 2 groups (d) in the case of female rats in feeding trial B
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Discussion
The compositional analysis of the diets showed that the dif-
ferences between the diets containing near-isogenic non-
GM maize, MON810 maize or conventional maize varie-
ties were minor and not considered to impair the health of 
the test animals. The reported higher than actual level of 
MON810 maize in diets (approximately 50 % as compared 
to the expected 33 %) is likely to be related to the uncer-
tainty inherent to the quantitative DNA-based analysis of the 
maize ingredient, which compares the content of GM maize 
DNA (copy number of transgenic DNA insert) with that of 
Table 8  Clinical biochemistry parameters (cage mean ± SD) in the serum of male and female Wistar Han RCC rats in the feeding trial B
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin, TP total protein, GLU glucose, CREA 
creatinine, U urea, CHOL cholesterol, TRG triglycerides, Ca calcium, Cl chloride, K potassium, Na sodium, P phosphorus. Except where indi-
cated (* n = 15; ** n = 14), the number of analysed rats was 16
a
 Statistically significant difference to the control value based on one-way ANOVA and post hoc t test (p ≤ 0.01) as well as with the Dunnett test 
(p ≤ 0.05)
(a)
 Statistically significant difference to the control value (p < 0.05) based on one-way ANOVA and post hoc t test, but not with the Dunnett test
b
 Statistically significant difference to the control value (p < 0.05) based on the Wilcoxon test
c
 Statistically significant difference to the control value based on the 95 % confidence interval of the SES
Parameter Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % PR32T16 11 % PR33D48 + 22 % 
PR32T16
33 % PR33D48 33 % PR32T83 33 % DKC6815
Male rats
 ALP (µkat/l) 1.34 ± 0.20 1.39 ± 0.13* 1.50 ± 0.17 1.37 ± 0.20 1.24 ± 0.08
 ALT (µkat/l) 0.61 ± 0.05 0.60 ± 0.07* 0.61 ± 0.04 0.64 ± 0.04 0.69 ± 0.20
 AST (µkat/l) 0.96 ± 0.16 1.00 ± 0.08* 1.02 ± 0.14 0.97 ± 0.14 0.94 ± 0.13
 ALB (g/l) 33.61 ± 1.07 33.85 ± 1.72* 33.27 ± 1.70 33.63 ± 0.73 32.43 ± 2.37
 TP (g/l) 59.59 ± 1.34 59.83 ± 3.66* 58.93 ± 4.28 59.20 ± 2.25 59.27 ± 2.49
 GLU (mmol/l) 9.41 ± 1.72 9.21 ± 1.32* 9.22 ± 1.95 10.52 ± 1.95 10.28 ± 1.58
 CREA (µmol/l) 41.19 ± 6.92 41.68 ± 3.10* 41.28 ± 3.10 47.68 ± 6.46(a),b 44.40 ± 4.82
 U (mmol/l) 5.62 ± 0.42 6.20 ± 0.47*,b,c 6.45 ± 0.67(a),b,c 6.43 ± 0.78(a),b,c 6.63 ± 1.18a,b,c
 CHOL (mmol/l) 2.30 ± 0.24 2.26 ± 0.24* 2.45 ± 0.32 2.47 ± 0.24 2.17 ± 0.18
 TRG (mmol/l) 0.65 ± 0.37* 0.84 ± 0.40* 0.78 ± 0.22 0.54 ± 0.16 0.80 ± 0.14
 Ca (mmol/l) 2.40 ± 0.22* 2.75 ± 0.23*,a,b,c 2.73 ± 0.07a,b,c 2.42 ± 0.17 2.56 ± 0.18
 Cl (mmol/l) 109.81 ± 1.67 107.25 ± 6.24* 108.00 ± 3.75 107.75 ± 2.75 106.16 ± 2.89b,c
 K (mmol/l) 4.47 ± 0.14* 4.50 ± 0.43* 4.66 ± 0.24 4.58 ± 0.43 4.76 ± 0.53
 Na (mmol/l) 149.94 ± 0.78* 144.53 ± 5.40*,a,b,c 146.77 ± 3.07b,c 149.00 ± 2.30 147.50 ± 4.15
 P (mmol/l) 2.51 ± 0.16* 2.84 ± 0.19*,b,c 2.64 ± 0.22 2.48 ± 0.12 2.99 ± 0.95(a)
Female rats
 ALP (µkat/l) 0.55 ± 0.03 0.63 ± 0.10b 0.65 ± 0.14(a) 0.54 ± 0.05 0.59 ± 0.06*
 ALT (µkat/l) 0.51 ± 0.06 0.54 ± 0.03 0.58 ± 0.05(a),b,c 0.50 ± 0.10 0.53 ± 0.07*
 AST (µkat/l) 0.93 ± 0.11 0.96 ± 0.20 1.12 ± 0.19(a),c 1.00 ± 0.17 0.94 ± 0.10*
 ALB (g/l) 40.99 ± 4.98 37.69 ± 3.48 36.83 ± 3.28(a) 40.31 ± 1.94 41.32 ± 4.44*
 TP (g/l) 70.24 ± 4.32 62.79 ± 8.54(a) 61.26 ± 7.85a,b,c 65.41 ± 6.78 64.04 ± 4.57*,b,c
 GLU (mmol/l) 6.61 ± 0.97 6.87 ± 1.62 6.22 ± 1.08 6.45 ± 1.07 6.71 ± 1.29*
 CREA (µmol/l) 38.29 ± 3.95 40.86 ± 6.61 43.02 ± 4.53b 42.85 ± 6.94 41.71 ± 3.10*
 U (mmol/l) 5.20 ± 0.53 5.92 ± 0.73(a),c 5.83 ± 0.61 5.36 ± 0.52 6.30 ± 0.91*,a,b,c
 CHOL (mmol/l) 1.90 ± 0.22 2.07 ± 0.45* 1.81 ± 0.14 1.94 ± 0.22 2.04 ± 0.19*
 TRG (mmol/l) 0.47 ± 0.17 0.39 ± 0.23* 0.31 ± 0.11 0.39 ± 0.13 0.37 ± 0.13*
 Ca (mmol/l) 2.49 ± 0.16 2.80 ± 0.19*,a,b,c 2.66 ± 0.07(a),b,c 2.22 ± 0.20a,b,c 2.44 ± 0.12**
 Cl (mmol/l) 108.25 ± 1.71 108.56 ± 3.11* 107.63 ± 2.33 107.06 ± 2.69 107.06 ± 2.38*
 K (mmol/l) 4.05 ± 0.33 4.34 ± 0.71* 3.96 ± 0.41 4.69 ± 1.11 4.34 ± 0.53**
 Na (mmol/l) 152.19 ± 2.02 151.81 ± 4.99* 147.44 ± 2.40a,b,c 150.38 ± 3.66 149.19 ± 2.96**,c
 P (mmol/l) 2.32 ± 0.22 2.52 ± 0.42* 2.22 ± 0.42 2.43 ± 0.28 2.52 ± 0.27**
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the total maize DNA (copy number of a gene common to the 
same crop, both GM and non-GM) present in the same sam-
ple. This uncertainty, for example, relates to issues of ploidy 
and zygosity within the different tissues present in a maize 
kernel (including embryo, endosperm and pericarp), as fur-
ther reviewed in more detail elsewhere (Holst-Jensen et al. 
2003; Chaouachi et al. 2013).
The trypsin inhibitor level was higher in the 33 % GMO 
diet in study A, yet the level measured (1.71 TIU/mg) was 
slightly above the limit of quantification and well below 
the level tolerated by laboratory rats (27.8 TIU/mg; Rackis 
et al. 1974). Moreover, no pancreatic hypertrophy, which is 
readily observed in rats exposed to soybean trypsin inhibi-
tor (Rackis 1965), was observed in the present study. The 
Table 9  Relative weight of the organs (cage mean ± SD) of male and female Wistar Han RCC rats in the feeding trial B
a
 Statistically significant difference to control group based on one-way ANOVA, post hoc t test (p < 0.01), post hoc Dunnett test (p < 0.05)
(a)
 Statistically significant difference to control group (p < 0.05) based on one-way ANOVA and post hoc t test, post hoc Dunnett test not signifi-
cant
b
 Statistically significant difference to control group (p < 0.05) based on Wilcoxon test
c
 Statistically significant difference to control group based on 95 % confidence interval of the SES
Organ Number  
of animals
Relative organ weights (organ weight/body weight × 100)
Control 11 % GMO 33 % GMO Conventional 1 Conventional 2
33 % DKC6666 11 % DKC6667-YG  
+ 22 % DKC6666
33 % DKC6667-YG 33 % PR33W82 33 % SY-NEPAL
Male rats
 Kidney (right) 16 0.293 ± 0.019 0.292 ± 0.015 0.285 ± 0.019 0.289 ± 0.011 0.298 ± 0.015
 Kidney (left) 16 0.283 ± 0.019 0.293 ± 0.014 0.291 ± 0.020 0.281 ± 0.014 0.294 ± 0.017
 Spleen 16 0.197 ± 0.014 0.196 ± 0.013 0.194 ± 0.020 0.190 ± 0.015 0.187 ± 0.017
 Liver 16 2.305 ± 0.294 2.267 ± 0.088 2.304 ± 0.093 2.230 ± 0.102 2.287 ± 0.215
 Adrenal gland (right) 16 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.005 ± 0.001 0.006 ± 0.001
 Adrenal gland (left) 16 0.007 ± 0.002 0.007 ± 0.002 0.007 ± 0.001 0.007 ± 0.001 0.007 ± 0.001
 Lung 16 0.304 ± 0.016 0.340 ± 0.020a,c 0.324 ± 0.046 0.315 ± 0.016 0.343 ± 0.030a,c
 Heart 16 0.225 ± 0.010 0.233 ± 0.013 0.232 ± 0.013 0.225 ± 0.006 0.228 ± 0.012
 Thymus 16 0.120 ± 0.018 0.121 ± 0.023 0.105 ± 0.013 0.105 ± 0.025 0.107 ± 0.010
 Pancreas 16 0.141 ± 0.026 0.129 ± 0.011 0.126 ± 0.013 0.137 ± 0.016 0.127 ± 0.013
 Testis (right) 16 0.472 ± 0.039 0.501 ± 0.057 0.468 ± 0.032 0.484 ± 0.046 0.473 ± 0.022
 Testis (left) 16 0.475 ± 0.038 0.514 ± 0.059 0.471 ± 0.043 0.475 ± 0.024 0.473 ± 0.027
 Epididymis (right) 16 0.147 ± 0.012 0.159 ± 0.016 0.160 ± 0.024 0.153 ± 0.009 0.153 ± 0.007
 Epididymis (left) 16 0.151 ± 0.013 0.162 ± 0.018 0.150 ± 0.020 0.153 ± 0.009 0.159 ± 0.007
 Brain 16 0.522 ± 0.027 0.545 ± 0.035 0.526 ± 0.045 0.526 ± 0.015 0.536 ± 0.029
Female rats
 Kidney (right) 16 0.317 ± 0.022 0.322 ± 0.017 0.320 ± 0.025 0.324 ± 0.016 0.321 ± 0.020
 Kidney (left) 16 0.322 ± 0.023 0.314 ± 0.021 0.313 ± 0.023 0.313 ± 0.021 0.323 ± 0.019
 Spleen 16 0.260 ± 0.028 0.249 ± 0.011 0.254 ± 0.029 0.255 ± 0.031 0.262 ± 0.024
 Liver 16 2.404 ± 0.135 2.398 ± 0.076 2.487 ± 0.137 2.474 ± 0.249 2.534 ± 0.320
 Adrenal gland (right) 16 0.013 ± 0.001 0.013 ± 0.001 0.015 ± 0.003 0.014 ± 0.002 0.012 ± 0.001
 Adrenal gland (left) 16 0.014 ± 0.001 0.015 ± 0.001 0.016 ± 0.002 0.015 ± 0.002 0.015 ± 0.002
 Lung 16 0.431 ± 0.020 0.431 ± 0.013 0.459 ± 0.079 0.455 ± 0.023b 0.423 ± 0.031
 Heart 16 0.267 ± 0.009 0.274 ± 0.012 0.282 ± 0.017(a) 0.272 ± 0.018 0.269 ± 0.006
 Thymus 16 0.132 ± 0.012 0.152 ± 0.019(a),b,c 0.160 ± 0.009a,b,c 0.144 ± 0.022 0.135 ± 0.015
 Pancreas 16 0.188 ± 0.018 0.164 ± 0.029 0.172 ± 0.023 0.161 ± 0.034(a) 0.176 ± 0.021
 Uterus 16 0.206 ± 0.041 0.236 ± 0.041 0.225 ± 0.077 0.181 ± 0.031 0.179 ± 0.049
 Ovary (right) 16 0.026 ± 0.005 0.027 ± 0.004 0.029 ± 0.005 0.025 ± 0.004 0.028 ± 0.005
 Ovary (left) 16 0.026 ± 0.002 0.025 ± 0.003 0.026 ± 0.004 0.025 ± 0.004 0.030 ± 0.003(a),b,c
 Brain 16 0.839 ± 0.032 0.860 ± 0.031 0.854 ± 0.034 0.873 ± 0.041 0.834 ± 0.040
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source of the trypsin inhibitor could have been the maize 
as well as the soybean used for the preparation of the diets.
The mycotoxins fumonisin B1, fumonisin B2 and deox-
ynivalenol were detected in some of the diets, although at 
levels that were slightly above the limit of quantitation, well 
below regulatory limits and not considered to affect animal 
health. Diets were found to contain residues of deltamethrin, 
ethoxyquin, piperonyl butoxide and pirimiphos-methyl, 
which were not present in the original maize samples (Kleter 
2014) and therefore probably originated from other dietary 
ingredients. The presence of ethoxyquin and pirimiphos-
methyl might also relate to their secondary use as antioxidant 
and post-harvest grain protectant, respectively. The residue 
levels were well below regulatory limits and did not raise 
concerns regarding potential impacts on animal health.
The MON810 event was detected in the diets containing 
the GM maize at the expected levels. Moreover, low levels 
of MON810 were present in the conventional maize varie-
ties PR33W82 and PR32T83 (Kleter 2014) as well as in the 
corresponding diets, but it was not possible to identify the 
source of the contamination. These low levels of admixture 
were not considered to impact on the validity of the results 
obtained in the feeding trials.
The EFSA Guidance on conducting a repeated-dose 
90-day oral toxicity study in rodents on whole food/feed 
(EFSA Scientific Committee 2011) recommends that his-
torical background data on variations in endpoint values 
should primarily be obtained from databases available in 
the actual testing facility or in the public domain. Since no 
adequate historical background data were available at the 
Slovak Medical University, two additional conventional 
maize varieties were included in each of the two feeding 
trials. Moreover, the historical background data supplied by 
the breeder company (Harlan) and available in the public 
domain are used as a reference at certain points in the fur-
ther discussion.
There were no statistically significant differences 
between the mean body weights of the five experimental 
groups in each feeding trial. The body weight of the male 
Wistar Han RCC rats at the end of both feeding trials 
reached a value of about 410–430 g/animal, while that of 
the female rats was about 250 g/animal. These values are 
in line with historical data for control animals of the same 
strain and age obtained from the breeder company (Harlan 
Laboratories 2014) and show that the one-week period of 
high temperature in the animal housing facility due to a 
defect in the air conditioning system, which evidently led 
to a decreased feed consumption for a week, did not affect 
the growth of the animals.
The ophthalmological alterations are not considered 
to be related to the diets supplemented with the different 
maize varieties, since they were observed in a low number 
of animals spread among the different experimental groups, 
were present at the very beginning but not at the end of 
the feeding trials and were not dose dependent (when the 
data of the 11 % GMO- and 33 % GMO-fed rats were 
compared).
The haematology parameters including the differential 
leucocyte counts in control and GMO-fed rats in the feed-
ing trial A were mostly similar, while various haematology 
parameters were significantly different when the data from 
control and GMO-fed rats in the feeding trial B were com-
pared. However, the measured values showed in most cases 
no dose–effect relationship and/or were within or close to 
the ranges of the groups fed the two conventional maize 
varieties. Furthermore, the values were within the range 
described for the individual parameters in control animals 
of the same strain and age (Harlan Laboratories 2014), 
so that the described alterations are not considered to be 
related to the diets supplemented with the two MON810 
maize varieties.
A significant increase of ALP, ALT and AST activi-
ties above the normal range in the serum of rats is a sign 
of liver toxicity. In the case of the female rats in feeding 
trial A, the ALT activity in the 11 % GMO group as well 
as the ALP activity in the 11 % GMO and 33 % GMO 
Table 10  Histological findings 
in male and female Wistar Han 
RCC rats set in the feeding 
trial B
Organ Histological finding 33 % isogenic  
non-GM maize
33 % MON810 
maize
Males
 Adrenal gland Cortex vacuolisation 1/16 0/16
 Epididymis Focal epididymitis 0/16 1/16
 Heart Mononuclear cell nodule 0/16 2/16
 Prostate Interstitial mononuclear infiltration 2/16 1/16
Focal fibrosis, prostatitis 0/16 1/16
Females
 Uterus Mucification of the endometrial  
epithelium
0/16 1/16
 Mesentery Lipoma 0/16 1/16
2312 Arch Toxicol (2014) 88:2289–2314
1 3
groups was significantly increased when compared to the 
animals receiving the control diet. The ALT activity in the 
11 % GMO group is close to the range of the groups fed 
conventional maize varieties. Since no significant differ-
ence was observed in the 33 % GMO group, the identified 
change in the 11 % GMO group is regarded as an inciden-
tal finding. Moreover, the changes in ALP activity were not 
dose dependent, and the activities measured in the serum 
of 11 % GMO- and 33 % GMO-fed female rats are in the 
same range as the historical data collected by the breeder 
company for control animals of the same strain, age and 
gender (Harlan Laboratories 2014). Furthermore, the AST 
activity was similar to that of the control diet-fed animals, 
and no sign of liver injury was observed in the gross nec-
ropsy as well as the histopathological analyses. Therefore, 
it is concluded that the GMO diet did not lead to hepato-
toxicity. This assumption is supported by the fact that the 
GMO diet did not lead to an increase of ALP, ALT and AST 
activities in the serum of GMO-fed male rats in the feeding 
trial A.
In the feeding trial B, the ALT and AST activities were 
significantly increased in the serum of female rats being 
fed the 33 % GMO diet if compared to the animals receiv-
ing the control diet. However, the ALT and AST activities 
measured in the serum of 33 % GMO-fed female rats are 
in the same range as the historical ALT and AST data col-
lected by the breeder company for control animals of the 
same strain, age and gender (Harlan Laboratories 2014). 
Furthermore, the ALP activity was similar to that of the 
control diet-fed animals, and no sign of liver injury was 
observed in the gross necropsy as well as the histopatho-
logical analyses. It is thus concluded that the GMO diet did 
not lead to hepatotoxicity. This assumption is supported 
by the fact that the GMO diet did not lead to an increase 
of ALP, ALT and AST activities in the serum of GMO-fed 
male rats in the feeding trial B.
The TP level was significantly lower in the serum of 
male rats fed the 11 % GMO and 33 % GMO diet in the 
feeding trial A and in that of female rats fed the 33 % GMO 
diet in the feeding trial B if compared to the correspond-
ing control animals. Taking into account that the magnitude 
of the differences between the groups was small and that 
no such decreases were observed in the female rats fed the 
11 % GMO and 33 % GMO diets in the feeding trial A as 
well as in the male rats fed the 11 % GMO and 33 % GMO 
diet in the feeding trial B, the effects are not considered to 
be related to the feeding of the GMO-containing diets.
GLU, CHOL and TRG levels were higher in male rats 
fed the 11 % GMO and the 33 % GMO diets in the feed-
ing trial A. Based on the fact that GLU, CHOL and TRG 
were not altered in female rats fed the GMO diets in the 
feeding trial A as well as in male and female rats fed the 
GMO diets in the feeding trial B and that the measured 
values were within or close to the ranges of the groups fed 
the conventional maize varieties, the described alterations 
are not considered to be related to the GMO diet used in the 
feeding trial A.
The Na and Cl levels in the serum of male rats fed the 
11 % GMO and the 33 % GMO diets as well as the Na con-
centration in the serum of female rats fed the 11 % GMO 
diet in the feeding trial A were significantly increased 
when compared to the control diet-fed animals. This was 
due to very high individual values, but these could not be 
excluded as outliers from the study. The increased Na and 
Cl serum concentrations are not considered to be a conse-
quence of feeding GMO-containing diets to the animals 
and an associated renal toxicity, since the increases were 
not dose dependent, the U and CREA serum levels (two 
parameters that are increased in cases of kidney dysfunc-
tion) were not significantly altered in male rats fed the 
11 % GMO and the 33 % GMO diets as well as in female 
rats fed the 11 % GMO diet in the feeding trial A and no 
histopathological alterations were observed in the kidneys 
of male and female rats fed the 33 % GMO diet.
The Ca, K and P levels were inconsistently altered in 
rats fed the GMO diets in both feeding trials. Nevertheless, 
the measured Ca, K and P values were within or close to 
the ranges of the groups fed the conventional maize varie-
ties and in the same range as the historical Ca, K and P data 
collected by the breeder company for control animals of the 
same strain, age and gender (Harlan Laboratories 2014). 
Therefore, the described alterations are not considered to 
be related to the diets supplemented with the two MON810 
maize varieties.
Gross necropsy findings were observed in a limited num-
ber of animals per group and were randomly distributed 
among the different experimental groups, so that they are 
not considered to be related to the feeding of GMO-con-
taining diets. Histopathological changes were only sporadi-
cally observed (i.e. at the most in 1–2 out of 16 animals) in 
a limited number of organs and were randomly distributed 
among the control diet and 33 % GMO diet-fed rats, and the 
frequency and nature of the findings (with the exception of a 
lipoma in a female rat fed the 33 % GMO diet in the feeding 
trial B) are typical for control animals of the same strain and 
age, so that it is concluded that the changes are not related 
to the feeding of GMO-containing diets.
Previous studies in mice (Vázquez-Padrón et al. 2000) 
and Atlantic salmon juveniles (Gu et al. 2014) as well as 
in bovine intestinal epithelial cells (Shimada et al. 2006) 
suggested that the Bt toxin might affect the gut barrier. The 
histopathological analyses in the present study show that at 
least in Wistar rats, the Bt toxin did not alter the normal 
histology of the small and large intestine. In line with the 
general outcome of the two 90-day feeding trials described 
in this report is a previous study in Sprague–Dawley rats 
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(Liu et al. 2012). Liu et al. (2012) fed Sprague–Dawley rats 
the genetically modified BT-38 maize in a concentration of 
up to 50 % in the diet for 90 days: no adverse effects were 
observed in rats consuming the GM maize when compared 
to the corresponding control animals, and no Cry1Ac-M 
protein was detected in the serum of rats fed the BT-38 
maize for 3 months. In a study by Gu et al. (2014), Atlan-
tic salmon juveniles were fed diets containing Bt-maize in 
a concentration of about 20 % for up to 99 days. The Bt-
maize containing diets did not affect the survival, growth 
performance, feed utilisation as well as liver, intestinal 
tract and skeletal morphology and development of the fish. 
However, the Bt-maize diets significantly reduced the activ-
ity of the digestive enzymes leucine aminopeptidase and 
maltase and the intestinal bile salt concentration, while 
they decreased amylase activity at certain sampling points. 
The authors concluded that the above-mentioned responses 
were not biologically significant, as they did not impact 
general fish health (Gu et al. 2014).
In the case of the haematology, clinical biochemistry 
and relative organ weight data of the two feeding trials, the 
significances obtained with the “classical” statistical analy-
sis procedures (ANOVA followed by both the t test and the 
Dunnett test as well as the Kruskal–Wallis test followed by 
the Wilcoxon test) and those identified by SES confidence 
interval analyses were similar, i.e. all approaches showed 
almost equal tendencies in group and endpoint differences. 
When applying the Dunnett post hoc test, the number of 
significances was reduced by those endpoint pairs in which 
the t test showed a p value between 0.01 and 0.05 (signifi-
cant, but not highly significant) according to the adjustment 
of the error rate for multiple comparisons. Nevertheless, the 
proportion of group differences remained.
When looking at the results obtained in the feeding tri-
als with the two MON810 maize varieties, it is obvious that 
statistically significant differences exist regarding a number 
of parameters between the control groups and the groups 
being fed the GMO diets for 90 days, whereby, except for 
the increased P levels in male rats fed the 11 % GMO diet, 
the statistically significant differences do not coincide in 
the two feeding trials. Due to this discrepancy, the differ-
ences are unlikely to be MON810 event specific. Based 
on the arguments mentioned in the preceding paragraphs, 
the differences between the control groups and the groups 
being fed the GMO diets are considered not to be relevant 
from a toxicological point of view. At the present time, a 
one-year feeding study with the MON810 maize is being 
performed by the GRACE consortium. The results of this 
feeding trial will show whether the differences observed 
after 90 days are reproducible and whether toxicologically 
relevant effects occur after long-term exposure.
Based on the fact that most of the measured values for 
the individual parameters were within the range described 
in control animals of the same strain and age, the genetic 
background of the plants seems not to influence the out-
come of the feeding trials from a toxicological point of 
view. In each feeding trial, two conventional maize varie-
ties were included. The results obtained when feeding rats 
with the near-isogenic non-GM maize and the conven-
tional maize varieties were mostly similar. In those cases, 
in which statistically significant differences between the 
control group and the groups fed the conventional maize 
varieties were observed, the measured values were within 
the range described for the individual parameters in control 
animals of the same strain and age.
In conclusion, the feeding trials performed with two 
MON810 maize varieties in the frame of the GRACE pro-
ject show that the MON810 maize at a level of up to 33 % 
in the diet does not lead to toxicologically relevant effects 
in male and female Wistar Han RCC rats after a 90-day 
exposure. An extended statistical analysis will be published 
in a separate follow-up paper. A combined analysis of the 
results described in this study together with the findings of 
an ongoing one-year feeding trial as well as of a number of 
in vitro studies, all of them being performed in the frame 
of the GRACE project, will allow: (1) to evaluate the appli-
cability and performance requirements of 90-day and one-
year feeding trials as part of the safety assessment of whole 
GM foods and feed; (2) to assess the necessity of prolonged 
(>90 days long) toxicity studies to evaluate the safety of a 
GM plant being part of whole GM foods and feed; (3) to 
evaluate the added value of animal feeding trials in the 
frame of the safety assessment of whole GM foods and feed.
The interpretations and conclusions in this section take 
into account the discussions and comments received in a 
second stakeholder consultation step including a two-day 
workshop attended by 56 stakeholder representatives and 
a written consultation procedure receiving detailed com-
ments from 12 stakeholder representatives. All comments 
provided by stakeholders as well as the answers of the 
GRACE team were documented in consultation reports 
and scheduled for publication at the project website (www.
grace-fp7.eu).
In line with the GRACE transparency policy, all raw data 
to be obtained in the frame of GRACE, including the clini-
cal, ophthalmological, haematology, clinical biochemistry, 
organ weight, necropsy and histopathology data presented 
in this study, will be made accessible to any interested per-
son through an internet portal named CADIMA (Central 
Access Database for Impact Assessment of Crop Genetic 
Improvement Technologies; www.cadima.info).
Acknowledgments This study was carried out as part of the 
GRACE project (“GMO Risk Assessment and Communication of 
Evidence”), financially supported by the 7th Framework Programme 
of the European Community for Research, Technological Develop-
ment and Demonstration Activities (FP7), Grant Agreement No. 
2314 Arch Toxicol (2014) 88:2289–2314
1 3
311957, as well as the Dutch Ministry of Economic Affairs and vari-
ous other co-sponsors. For the analyses of maize and diets, analytical 
result summaries were provided by INRA and RIKILT Wageningen 
UR as partners of the GRACE consortium as well as the companies 
Covance, Harlan and Mucedola contracted by GRACE. The authors 
are particular grateful to a broad range of stakeholder representatives 
who attended the GRACE workshops, engaged in discussions and 
provided valuable comments in writing on draft study plans as well as 
on the study results, their draft interpretations and conclusions.
Conflict of interest Kerstin Schmidt provides consulting ser-
vices in the field of biostatistics and has advised National and Euro-
pean Authorities, biotech and pharmaceutical companies as well as 
research institutions, also in the context of GMO risk assessment. 
Pablo Steinberg is a member of the Scientific Board of the Institut 
Danone Ernährung für Gesundheit e.V. (Munich, Germany).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
Chaouachi M, Bérard A, Saïd K (2013) Relative quantification in 
seed GMO analysis: state of art and bottlenecks. Transgenic Res 
22:461–476
EFSA Scientific Committee (2011) EFSA guidance on conducting 
repeated-dose 90-day oral toxicity study in rodents on whole 
food/feed. EFSA J 9:2438
Gu J, Bakke AM, Valen EC, Lein I, Krogdahl Å (2014) Bt-maize 
(MON810) and non-GM soybean meal in diets for Atlantic 
salmon (Salmo salar L.) juveniles—impact on survival, growth 
performance, development, digestive function, and transcriptional 
expression of intestinal immune and stress responses. PLoS ONE 
9:e99932
Harlan Laboratories (2014) Historical and current background data: 
RccHanTM:WIST rats. http://webapps.harlan.com/wistarhannover
Hill M, Launis K, Bowman C, McPherson K, Dawson J, Watkins J, 
Koziel M, Wright MS (1995) Biolistic introduction of a synthetic 
Bt gene into elite maize. Euphytica 85:119–123
Holst-Jensen A, Rønning SB, Løvseth A, Berdal KG (2003) PCR 
technology for screening and quantification of genetically modi-
fied organisms (GMOs). Anal Bioanal Chem 375:985–993
Implementing Regulation (EU) (2013) Commission Implementing 
Regulation (EU) No. 503/2013 on applications for authorisation 
of genetically modified food and feed in accordance with Reg-
ulation (EC) No. 1829/2003 of the European Parliament and of 
the Council and amending Commission Regulations (EC) No. 
641/2004 and (EC) No. 1981/2006. (OJ L 157, 8.6.2013, p. 1–48)
Kleter G (2014) Summary report of analytical parameters measured 
in maize and diets prepared for the GRACE project’s first two 
series of 90-day feeding trials in rats (Studies A and B, April-July 
2013). http://www.cadima.info
Liu P, He X, Chen D, Luo Y, Cao S, Song H, Liu T, Huang K, Xu W 
(2012) A 90-day subchronic feeding study of genetically modi-
fied maize expressing Cry1Ac-M protein in Sprague-Dawley rats. 
Food Chem Toxicol 50:3215–3221
Nakagawa S, Cuthill IC (2007) Effect size, confidence interval and 
statistical significance: a practical guide for biologists. Biol Rev 
Camb Philos Soc 82:591–605 (see Erratum in: Biol Rev Camb 
Philos Soc 84: 515, 2009)
OECD (1998) Guidelines for the Testing of Chemicals, Section 4, 
OECD Publishing. doi:10.1787/9789264070707-en
Rackis JJ (1965) Physiological properties of soybean trypsin inhibi-
tors and their relationship to pancreatic hypertrophy and growth 
inhibition of rats. Fed Proc 24:1488–1493
Rackis JJ, McGhee JE, Booth AN (1974) Biological threshold lev-
els of soybean trypsin inhibitors by rat bioassay. Cereal Chem 
52:85–92
Schmidt K, Schmidtke J (2014) Statistical analysis report on a 90-day 
feeding study in rats with Monsanto MON810 maize and Pioneer 
MON810 maize. http://www.cadima.info
Schnepf E, Crickmore N, Van Rie J, Lereclus D, Baum J, Feitelson J, 
Zeigler DR, Dean DH et al (1998) Bacillus thuringiensis and its 
pesticidal crystal proteins. Microbiol Rev 62:775–806
Shimada N, Miyamoto K, Kanda K, Murata H (2006) Binding of 
Cry1Ab toxin, a Bacillus thuringiensis insecticidal toxin, to pro-
teins of the bovine intestinal epithelial cell: an in vitro study. 
Appl Entomol Zool 41:295–301
Vázquez-Padrón RI, Gonzáles-Cabrera J, García-Tovar C, Neri-Bazan 
L, Lopéz-Revilla R, Hernández M, Moreno-Fierro L, de la Riva 
GA (2000) Cry1Ac protoxin from Bacillus thuringiensis sp. 
kurstaki HD73 binds to surface proteins in the mouse small intes-
tine. Biochem Biophys Res Commun 271:54–58
Waigmann E, Gomez A, Lanzoni A, Perry JN (2013) Editorial: New 
Commission Implementing Regulation on Risk Assessment of 
GM plant applications: novel elements and challenges. EFSA  
J 11:e11121
